As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other…
Quantum leaps in drug discovery? NobleAI joins forces with Microsoft while King’s College London aligns with Kvantify
The word “revolutionize” gets thrown around a lot in describing the potential of emerging technologies. But quantum computing could make good on the promise to disrupt healthcare applications ranging from drug discovery to medical imaging. Theoretically, a quantum computer with 300 quantum bits (qubits) could crunch more calculations in an instant than there are atoms…
A year in review: AI’s evolving role in drug discovery and development in 2023
In the realm of drug discovery, AI is making waves, and 2023 could potentially be a pivotal year for this technology. As the technology enters the popular consciousness, pharma employees are wondering “why they can’t have similar AI-driven tools for their professional tasks,” said Diane Wuest, head of digital R&D at Sanofi, in a recent…
NLP in drug discovery and the quest for the ‘right’ research elements
In drug discovery and development, data sources are as diverse as they are plentiful. There are comprehensive databases brimming with molecular targets, cellular processes, genomic sequences, proteomic profiles, and metabolite patterns that shed light on disease pathways. Data possibilities in the patient care realm are similarly vast, spanning electronic medical records, imaging datasets, and even…
The evolution of drug discovery: Opportunities and obstacles with ML and AI development
The potential for artificial intelligence (AI) and machine learning (ML) to reshape drug discovery and development is immense. From expediting learning and driving discoveries to managing large-scale data sets and generating fresh insights, the true scale of AI’s influence on the industry is only starting to be understood. But with great potential comes great responsibility.…
Novo Nordisk stops once-weekly semaglutide kidney outcomes trial early following interim analysis
Novo Nordisk will halt the phase 3b FLOW trial, which investigated the effects of once-weekly injectable semaglutide on kidney outcomes in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD). The company reached the decision following the recommendation of the independent Data Monitoring Committee (DMC), following an interim analysis that met pre-specified criteria…
From FTC’s tightened grip to PULSE Coalition: A timeline of the life science M&A landscape
The biopharma industry is pushing back against increased scrutiny of mergers and acquisitions from the Federal Trade Commission (FTC). More than 30 biopharma companies and industry associations announced the formation of the Partnership for the U.S. Life Science Ecosystem (PULSE) to advocate for the role of M&A activity in the biopharma sector. A M&A landscape…
How data-savvy are you in drug discovery?
Hey there, drug discovery professionals: Ever wondered where you stand in the grand scheme of drug discovery data-savviness? We’ve created a short quiz to help you get an idea. Drug discovery and development is an increasingly data-intensive field, underscoring the need for data science to be a core drug discovery discipline. The industry has taken…
Ginkgo Bioworks and Google Cloud forge five-year AI and biology partnership
Founded in 2008, Ginkgo Bioworks’ stock jumped almost 25% on August 29, hitting $2.22, after unveiling a five-year partnership with Google Cloud. The partnership centers around the development of novel AI tools for biology and biosecurity. In particular, Ginkgo hopes to further its mission to make biology easier to engineer in the AI era. Opting…
Assessing the techbio landscape: hype or substance?
The venture capital firm Artis Ventures, founded in 2001, coined the term “techbio” sector to describe biotech platforms where technology and engineering take the lead in advancing drug discovery and biomanufacturing. In circa 2019, the firm contributed to shaping the techbio landscape by setting up venture capital fund named Artis techbio that bridges the gap…
Nvidia exec: Generative AI can turn every biologist into a computer scientist — and vice versa
On a recent visit to Nvidia’s headquarters in Santa Clara, I had the chance to speak with Kimberly Powell, the company’s vice president and general manager of healthcare. After asking about the pharma industry’s surging interest in AI, Powell remarked, “Every pharma knows who Nvidia is now.” Curious, I asked her, “How long has that…
A checklist for unlocking the promise of AI in clinical trials
AI algorithms offer a myriad of advantages for clinical trials. AI techniques can, for instance, support patient enrollment and site selection, improve data quality and enhance patient outcomes. AI algorithms — combined with an effective digital infrastructure — can also help aggregate and manage clinical trial data in real time, as Deloitte has noted. Last…
In data we trust: AI’s growing influence on drug development
The journey to developing a successful drug, theoretically, may appear linear: you discover the right drug, find the suitable patient and administer it at the right time. The reality, however, often deviates from this straightforward path. Aligning these three variables remains notoriously difficult, often leading to elongated timelines strewn with failures, sometimes extending over a…
Visualizing automation’s influence on drug discovery careers
Today, the pharma sector, like many others, appears to be on the cusp of a transformation thanks to the influence of automation on drug discovery careers. Companies ranging from Insilico Medicine to Big Pharma firms like Janssen and Sanofi are putting AI at the heart of their operations. Many are increasingly recruiting workers from the…
Synthetica Bio lates to tap generative AI to spur drug discovery innovation
Interest in generative AI has skyrocketed in 2023. While the generative AI market is already substantial, worth $10 billion in 2022 according to Grand View Research, it is set to balloon by a compound annual growth rate (CAGR) of 35.6% from 2023 to 2030. It’s no wonder that a slew of companies — including Exscientia,…
Microsoft details how its technology is advancing drug discovery and biomedical research
As cloud technology matures, life-sciences companies are finding new avenues for business value in life sciences, extending beyond the cost efficiencies typically associated with cloud migrations, as McKinsey noted. In an email statement, Microsoft outlined how its own cloud computing, AI and research capabilities are driving similar innovation for biopharma companies. This article explores Microsoft…
Microsoft goes all in on Azure Quantum to accelerate scientific discovery
In the rapidly evolving landscape of quantum computing, Microsoft is pushing the boundaries with its Azure Quantum platform. As Microsoft CEO Satya Nadella recently announced, “Our goal is to compress the next 250 years of chemistry and material science progress into the next 25,” Nadella said. The executive also noted that, thanks to recent advances…
Bridging bioanalytical gaps: Examining validation methods across species
Bioanalytical method validation is the backbone of effective drug discovery and development. Its pivotal role ensures the generation of reliable and reproducible data from diverse species, leading to safe and effective therapeutics. As critical as this process is, scientists face many challenges, particularly regarding validation across different species in preclinical and clinical studies. Accommodating species…
Raising the efficiency floor and innovation ceiling with generative AI in drug discovery
Large language models (LLMs) such as ChatGPT promise advances that extend beyond capturing public interest. Because transformer models like GPT have an architecture that supports the understanding of language in context, they point to an array of novel possibilities for scientific research. “The transformer architecture is critical,” according to Michael Connell, the chief operating officer…
Quantum-inspired power could brighten drug discovery
In the realm of drug discovery, the Harvard-educated chemist Nick Paras, Ph.D. compares the early stages of identifying new compounds to a game of Zelda, in which a player at times must navigate through dark rooms and solve puzzles to progress. Similarly, medicinal chemists and biochemists too must traverse the vast, often obscure landscape of…
Quantum computing promises new frontier in drug discovery and bioinformatics
Quantum computing — described by pop astrophysicist Neil deGrasse Tyson as “computing with atoms” — is an emerging technology with a potential for immense computational speed and power. For some problems, quantum computers can be exponentially faster than classical computers, while for others the speedup may be more measured. The promise for drug discovery could…
SandboxAQ, bearing Alphabet’s DNA, eyes quantum-inspired breakthroughs in drug discovery
Emerging as a spinoff from Alphabet’s experimental division X, SandboxAQ recently pulled back the curtain on its latest endeavor — the biopharma molecular simulation division AQBioSim. The venture has attracted investments from significant figures like former Alphabet CEO Eric Schmidt, who is now the chair of Sandbox AQ, and Salesforce.com Inc. founder Marc Benioff’s Time…
Why AI alone won’t resolve drug discovery challenges
Big Pharma and researchers are sharpening their focus on AI to speed drug discovery. But the path to fully AI-driven drug discovery faces substantial hurdles, according to Adityo Prakash, CEO of Verseon. “When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms,” he…
iBio’s chief reveals strategy behind AI-driven bispecific antibody discovery plans
Biotech firm iBio (NYSEA:IBIO) has incorporated EngageTx, a machine learning-driven technology, into its development roadmap. This T-cell engaging antibody panel assists in generating bispecific antibodies targeting cancer cells. In particular, the firm is developing a novel Trophoblast Cell Surface Antigen 2 (TROP-2) bispecific molecule to target TROP-2-positive cancers. In addition to their focus on oncology,…
UBS: Generative AI is no silver bullet for drug discovery
Imagine a world where the process of developing life-saving drugs is as streamlined as a modern assembly line. In such a reality, generative AI in drug discovery might churn out promising compounds with similar efficiency and precision as a factory robot assembling a car. Moreover, such technology could chip away at the steep cost and…